Atypical HUS and PNH: better together?
The diseases PNH and aHUS, although different, share features in common. Both are very rare, both are the result of uncontrolled…
Is aHUS’ end nigh? It is now!
Nearly five years ago Global Action asked the question “ Is aHUS’s end nigh ?” In a trilogy of articles. (…
COVID Infection and vaccination and aHUS.
It was anticipated at the beginning of the pandemic that COVID would be a trigger of aHUS. Global Action postulated it…
aHUS Global Poll 2024- 7 days left.
There is now 7 days to go before the Global aHUS Poll is closed to further responses. This year Global aHUS…
The KDIGO “aHUS” Guidelines have arrived
The long anticipated KDIGO Guidelines from the Controversies Conference held in Florence in September 2022 are now published. The report can…
An aHUS Game Changer
A new blood test for aHUS could be a game changer for those who have been diagnosed with aHUS only to…
An eculizumab biosimilar for the USA
Global Action has received this notice from the FDA. We cannot find a price or evidence from an aHUS trial as…
An eculizumab biosimilar for USA
Global Action has received this notice from the FDA. Cannot find a price or evidence from an aHUS trial as yet.…
Newsletter: aHUS Global Advocate, 9th Edition
The aHUS Global Advocate Newsletter, highlights of news & views with a focus on the rare disease atypical HUS. Our 9th Edition, March 2024